| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
A critical assessment of leading companies, their research, products, partners and performance
The biopharmaceutical R&D sector is taking an ever more important role in the
minds of industry and investors. The potential to fundamentally alter
treatment regimes and cure, rather than symptomatically treat, many
life-threatening conditions grows greater, but questions remain:
- Who are the companies that are leading development in this critical area?
- What is their area of expertise?
- How substantial is their current product line-up or pipeline projects?
- With whom are they collaborating?
- How can you assess their strengths and weaknesses?
Who's Developing What in Global Biopharmaceuticals? is a new 425 page
management guide to 50 significant companies working in the field. From their
structure, through collaboration and detailed pipeline evaluation, the report
provides an unmatchable window to the future biopharmaceutical corporate
environment.
Important areas covered, where available, for each company include:
- Key Personnel - List of key management
- Company Overview
- Milestones - Summary table of key events in the company's history
- R&D Pipeline - Products/research by phase and indication
- Technology - Novel discovery/production technology platforms
- Agreements - Who's working with whom? Important alliances identified
- Key Financial Data - Essential P&L/funding data
- Appraisal & Evaluation - A critical assessment of the company's platform,
pipeline and corporate environment
Answering key questions such as...
- With which major pharmaceutical companies is French company Evotec
working, and on what?
- Optimer Pharmaceuticals has eight products in development - what stage
are they at and for what are they indicated?
- What benefit has Astex Therapeutics' Pyramid drug discovery platform
brought to the company?
TABLE OF CONTENTS
Affymax
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Technology
- Agreements
- Key Financial Data
- Appraisal & Evaluation
Ambit Bio sciences
Ambrx
Amylin Pharmaceuticals
Arana Therapeutics
ARCA biopharma
ARIUS Research
ARYx Therapeutics
Astex Therapeutics
BioVex
BioXel
Bruin Pharmaceuticals
Celectis
Combinatorx
Deltanoid Pharmaceuticals
Diatos
Evotec
Prime Therapeutics
Genmab A/S
Idenix Pharmaceuticals
Ikaria
Infinity Pharmaceuticals
Intercytex
Ironwod Pharmaceuticals
KAIPharmaceuticals
Kalypsys
Kereos
Micromet
Molecular Insight Pharmaceuticals
Neuromed Pharmaceuticals
Novexel
NPS Pharmaceuticals
Optimer Pharmaceuticals
Palatin Technologies
Pharmamar
Prana Biotechnology
Replidyne
S*BIO
Sosei
Spedel Pharmaceuticals
Synta Pharmaceuticals
Syntaxin
Takara Bio
Theravance
Tranzyme Pharma
Trimeris
Trubion Pharmaceuticals
ViroPharma
WILEX
Xencor
Espicom Analysis
|
